From Health Canada:
Novartis Pharmaceuticals Canada Inc., in consultation with Health Canada, would like to inform you of an increased risk of peripheral neuropathy observed in chronic hepatitis B patients treated with telbivudine (SEBIVO®) in combination with peginterferon alfa-2a (Pegasys®), compared to the interferon or telbivudine alone, during a controlled pilot clinical trial. An increased risk cannot be ruled out for treatments combining telbivudine with other interferon products (pegylated or standard).
For health care professionals
For the public
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment